Canaccord Genuity adjusted its outlook on Bioceres Crop Solutions (NASDAQ:BIOX), reducing the price target to $7.00 from the previous $9.50, while still advocating a Buy rating for the stock. The ...

Despite a 16% revenue increase, Canaccord Genuity Group Inc (CCORF) faces profitability hurdles due to rising expenses and US ...

Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...

TD Securities downgraded Canaccord Genuity (CCORF) to Hold from Buy with a price target of C$10, down from C$12.Maximize Your Portfolio with ...

Uncertainty around North American trade has hindered capital-markets activity and stalled investments in Canada, according to ...

Analysts at Canaccord Genuity lowered their target price on Colombia-focussed oil firm Arrow Exploration from 50.0p to 44.0p ...

Canaccord Genuity Group Inc (TSX:CF) is set to release its Q3 2025 earnings on Feb 4, 2025. The consensus estimate for Q3 ...

In a report released yesterday, Andrew Hodge from Canaccord Genuity maintained a Hold rating on ARB Corporation Limited (ARBFF – Research ...

Canaccord Genuity Group Inc. ( OTCPK:CCORF) Q3 2025 Earnings Conference Call February 5, 2025 8:00 AM ET Dan Daviau – Chairman and Chief Executive Officer Nadine Ahn – Deputy Chief Financial Officer ...

TORONTO , Feb. 4, 2025 /CNW/ - Canaccord Genuity Group Inc. (Canaccord Genuity Group, the Company) (TSX: CF) today announced its financial results for the third fiscal quarter and nine months ended ...